Impact of a Focal Muscle Vibration Protocol in Front of the the Anterior Tibial Muscle in the Subacute Post-stroke Period on Motor Recovery in Hemiplegic Patients. (VIBRATAC)

In about 40 percent of cases, after a stroke, neuromotor impairment leads to activity limitations and the development of chronic functional disorders, which have a significant impact on patient autonomy.

In the early subacute phase, motor deficit in foot lifters is one of the factors limiting standing posture and ambulation, which is ultimately difficult to rehabilitate due to the lack of available techniques for obtaining early onset of useful active voluntary contraction.

The use of muscular focal vibration therapy, applied to relaxed muscle, may be of interest due to the portability and availability of the system and the neuromotor benefits demonstrated in healthy subjects and in acute and chronic post-stroke patients.

Study Overview

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Saint-Etienne, France, 42055
        • Centre Hospitalier Universitaire de Saint-Etienne
      • Saint-Priest-en-Jarez, France
        • Le Clos Champirol - Service de Médecine Physique et de Réadaptation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Having had a stroke (with or without previous stroke) and being in the early subacute phase (between 14 days and 3 months of stroke).
  • Responsible for a motor deficit in the right or left lower limb.
  • No neurological history other than stroke.

Exclusion Criteria:

  • Multifocal stroke
  • Patient having received a botulinum toxin injection to the lower limb to be vibrated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: vibration program
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
evaluation of muscular strength score from 0 to 5
Assess functional walking and aerobic abilities
measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
score from 0 to 4 evaluation of spasticity
score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation. The program will apply a frequency of 100 Hz, with an amplitude of 1 mm
Sham Comparator: sham program
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.
assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination Score from 0 to 34
evaluation of muscular strength score from 0 to 5
Assess functional walking and aerobic abilities
measures the time it takes to get up from a chair, walk 10 feet, turn around, return to the seat and sit down
score from 0 to 4 evaluation of spasticity
score from 0 to 36 measures the patient's ability to maintain stable postures and balance in changes of position
analysis of static equilibrium parameters and positional measurement of the center of gravity on the Winposturo platform
a 4-week program of muscular focal vibrations, at the rate of 5 sessions of 30 minutes per week, in addition to conventional rehabilitation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
score of Fugl Meyer Assessment (lower limbs)
Time Frame: day 30
score from 0 to 34 Stroke-specific performance-based disability index that quantitatively assesses analytical motor skills in the lower limb.
day 30

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
score of Fugl Meyer Assessment (lower limbs)
Time Frame: day 0, day 15, day 30 and month 2
score from 0 to 34 Stroke-specific performance-based disability index that quantitatively assesses analytical motor skills in the lower limb.
day 0, day 15, day 30 and month 2
score of Medical Research Concil
Time Frame: day 0, day 15, day 30 and month 2
score of 0 (absence of contraction) to 5 (normal force)
day 0, day 15, day 30 and month 2
assess functional walking ability
Time Frame: day 0, day 15, day 30 and month 2
measured with 2 Minute Walk Test
day 0, day 15, day 30 and month 2
score of postural assessment scale for stroke
Time Frame: day 0, day 15, day 30 and month 2
measures the patient's ability to maintain stable postures, as well as balance in changes of position score of 0 (cannot perform the activity) to 36 (can perform the activity)
day 0, day 15, day 30 and month 2
analysis of static equilibrium
Time Frame: day 0, day 15, day 30 and month 2
with Winposturo platform
day 0, day 15, day 30 and month 2
positional measurement of the center of gravity
Time Frame: day 0, day 15, day 30 and month 2
with Winposturo platform
day 0, day 15, day 30 and month 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bruno FERNANDEZ, MD, CHU Saint Etienne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 14, 2021

Primary Completion (Actual)

September 29, 2023

Study Completion (Actual)

December 15, 2023

Study Registration Dates

First Submitted

January 28, 2021

First Submitted That Met QC Criteria

February 2, 2021

First Posted (Actual)

February 3, 2021

Study Record Updates

Last Update Posted (Actual)

December 27, 2023

Last Update Submitted That Met QC Criteria

December 26, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Fugl-Meyer Assessment (FMA)

Subscribe